Type 1 Gaucher Disease
Links shared publicly online about this topic
Vpriv available for Type 1 Gaucher disease - ONA
oncologynurseadvisor.com — “Shire announced that Vpriv (velaglucerase alfa for injection) has been FDA approved and made available for the treatment of Type 1 Gaucher disease.” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 1, 2010 at 4:13 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Vpriv available for Type 1 Gaucher disease http://goo.gl/fb/3kQb
Cheaper, More Effective Treatment of Type 1 Gaucher Disease Possible
opa.yale.edu — “Cheaper, More Effective Treatment of Type 1 Gaucher Disease Possible” View full resource at opa.yale.edu
Most Recently Shared on October 20, 2010 at 4:21 pm By:
School of Medicine Medical School
New light on Type 1 Gaucher Disease: http://bit.ly/9KneM0
Elelyso Approved for Type 1 Gaucher Disease --Doctors Lounge
doctorslounge.com — “Elelyso Approved for Type 1 Gaucher Disease --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on May 2, 2012 at 12:04 am By:
Elelyso Approved for Type 1 Gaucher Disease http://t.co/s2NSsCih #Health #Medicine
Cheaper, more effective treatment of type 1 Gaucher disease possible
labspaces.net — “Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.” View full resource at labspaces.net
Most Recently Shared on October 20, 2010 at 5:20 pm By:
Cheaper, more effective treatment of type 1 Gaucher disease possible - http://is.gd/g9XvV
Shire receives approval for VPRIV to treat type 1 Gaucher disease
news-medical.net — “Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on August 27, 2010 at 10:15 am By:
Shire receives approval for VPRIV to treat type 1 Gaucher disease: Shire, the global specialty biopharmaceutical c... http://bit.ly/d0YvUf
Pharmacy Europe - Study success for type 1 Gaucher disease
pharmacyeurope.net — “Pharmacy Europe, daily news for pharmacists, hundreds of clinical and best practice articles, online comment and video presentations.” View full resource at pharmacyeurope.net
Most Recently Shared on November 5, 2010 at 11:19 pm By:
Drugs and Devices OW OW Health
Study success for type 1 Gaucher disease: Shire Presents Positive New Data at the 60th Annual American Society o... http://bit.ly/9Xkfwt
OnePath Gaucher Application available for patients with Type 1 Gaucher disease
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.” View full resource at news-medical.net
Most Recently Shared on May 24, 2010 at 2:12 pm By:
OnePath Gaucher Application available for patients with Type 1 Gaucher disease: Shire plc, the global specialty bi... http://bit.ly/9enDrk
New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study
news-medical.net — “Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.” View full resource at news-medical.net
Most Recently Shared on October 20, 2010 at 10:06 am By:
Parkinson's Disease: New disease pathways involving more than one cell type lead to Type 1 Gaucher disease: Study:... http://bit.ly/9u2z3W
Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease
medicalnewstoday.com — “Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human ce” View full resource at medicalnewstoday.com
Most Recently Shared on May 29, 2010 at 1:06 pm By:
Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease http://mnt.to/3Dhn
Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease
medicalnewstoday.com — “Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the compan” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2009 at 2:28 pm By:
MNT Clinical Trials Health News
Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Ty.. http://bit.ly/7VIO1K
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on December 1, 2010 at 12:14 pm By:
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease: Shire plc, the global specia... http://bit.ly/eXIaXq
Shire Presents Positive Data For Patients With Type 1 Gaucher Disease Who Switched To VPRIV(TM)
healthcare.tweetmeme.com — “All the news on healthcare” View full resource at healthcare.tweetmeme.com
Most Recently Shared on March 27, 2010 at 2:23 pm By:
Healthcare TweetMeme Health Social Media
Shire Presents Positive Data For Patients With Type 1 Gaucher Disease Who Swi.. http://retwt.me/1MEM3 (via @lstmjournals)
Shire Presents Positive New Data At The 60th Annual American Society Of Human Genetics (ASHG) For Patients With Type 1 Gaucher Disease
medicalnewstoday.com — “Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of V” View full resource at medicalnewstoday.com
Most Recently Shared on November 5, 2010 at 1:37 pm By:
Shire Presents Positive New Data At The 60th Annual American Society Of Human Genetics (ASHG) For Patients With Type 1 .. http://dld.bz/5dhh
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy o” View full resource at news-medical.net
Most Recently Shared on July 2, 2010 at 11:52 am By:
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients: Shire... http://bit.ly/dbtzNQ
Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV
buzzup.com — “Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.” View full resource at buzzup.com
Most Recently Shared on March 26, 2010 at 11:39 am By:
Genetics News: Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who swit... http://buzzup.com/rnye
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
School of Medicine
Founded in 1810, Yale School of Medicine is a world-renowned center for biomedical research, education and advanced health care.
-
Doctors Lounge
DoctorsLounge medical community, news, discussions and blogs.
Advertisement
